Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

055IC - Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease & CRPC

Sunday, May 20
1:30 PM - 3:30 PM
Location: MCC WEST, 2009

There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer, Urologists are suddenly being confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA-repair gene mutations (present in >10% of men with metastatic disease!). This course will cover the state of the art in genetic testing and discuss the practical impact on patient care. Urologists will leave this course with a clear understanding of how to translate these latest scientific advances into their routine clinical practice, improving the care of these men who are at a markedly elevated risk of progression and death from prostate cancer.

Learning Objectives:

Todd M. Morgan

Associate Professor
University of Michigan

Todd M. Morgan, M.D. is Associate Professor of Urology at the University of Michigan and specializes in the treatment of genitourinary malignancies. His surgical expertise encompasses a wide spectrum of open, laparoscopic, and robotic surgeries. Dr. Morgan is a translational surgeon-scientist, and the primary focus of his laboratory is on identifying clinically relevant molecular approaches to predict response and resistance to treatment in genitourinary malignancies. This includes work in prostate cancer to develop blood and bone marrow-based assays that can guide precision-based therapeutic strategies in real time, as well as ongoing research in renal cell carcinoma to identify genomic signatures for risk stratification.

Dr. Morgan’s research ranges from preclinical and translational studies to prospective clinical trials. He is the principal investigator of the ongoing Genomics in Michigan Impacting Observation or Radiation (G-MINOR) trial, which is a biomarker-based study enrolling patients across 15 diverse sites in Michigan. Additionally, Dr. Morgan is working to understand how heritable mutations to genes such as BRCA2 should impact approaches to prostate cancer detection and management. As part of these efforts, he has opened the new Prostate Cancer Risk Clinic at the University of Michigan and launched a biomarker-driven clinical trial for early prostate cancer detection in men with germline mutations predisposing to aggressive prostate cancer.

Dr. Morgan has authored over 100 original publications and has received a number of awards, including from the Prostate Cancer Foundation, NCCN, and Society for Basic Urologic Research. He has served on several national guideline committees, such as the AUA Muscle-Invasive Bladder Cancer Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, and the ASCO Molecular Markers for Prostate Cancer Guidelines. His research is supported by multiple sources and includes funding from the Department of Defense, National Cancer Institute, and Prostate Cancer Foundation.

Presentation(s):

Send Email for Todd Morgan

Leonard Gomella

Thomas Jefferson University

Leonard G. Gomella, M.D., F.A.C.S. (Program Co-Chair)

Dr. Leonard Gomella is the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at the Sidney Kimmel Medical College. After general surgery and Urology training at the University of Kentucky he completed a fellowship in the Surgery Branch of the National Cancer Institute. He joined the Jefferson faculty in 1988 and was appointed Chair in 2002. He serves as Senior Director for Clinical Affairs for the Sidney Kimmel Cancer at Jefferson, Clinical Director of the SKCC Network and Urology Chair for NRG. He is currently Immediate Past President of the Society of Urologic Oncology. Dr. Gomella is involved in translational basic science and clinical research in the development of new diagnostic techniques and treatments for prostate and bladder cancer through the SKCC as Co-Leader of the Biology of Prostate Cancer Program. He led the team that published the first molecular studies of circulating micro metastasis in prostate cancer detected by RT-PCR. He has given over 500 presentations nationally and internationally and written over 400 papers, chapters and monographs. He is a consultant to over 2 dozen journals in the field of urology and oncology and in 2010 became Editor-in-Chief of the “Canadian Journal of Urology”. Dr. Gomella has also authored and edited 63 editions of 17 different books for medical students, residents, and practicing physicians and co authored the first book dedicated to prostate cancer for the general public "Recovering From Prostate Cancer" in 1993. In 2015 he received a “Distinguished Contribution Award” from the AUA and Jefferson honored him with the “Jefferson Achievement Award in Medicine”.

Presentation(s):

Send Email for Leonard Gomella


Assets

055IC - Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease & CRPC



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease & CRPC